
Subhasree Nag

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/925136/publications.pdf Version: 2024-02-01



SURHASDEE NAC

#	Article	IF	CITATIONS
1	The MDM2-p53 pathway revisited. Journal of Biomedical Research, 2013, 27, 254.	0.7	279
2	Ginsenosides as anticancer agents: In vitro and in vivo activities, structure–activity relationships, and molecular mechanisms of action. Frontiers in Pharmacology, 2012, 3, 25.	1.6	272
3	Targeting the NFκB Signaling Pathways for Breast Cancer Prevention and Therapy. Current Medicinal Chemistry, 2014, 22, 264-289.	1.2	178
4	Ribosomal Proteins and Human Diseases: Pathogenesis, Molecular Mechanisms, and Therapeutic Implications. Medicinal Research Reviews, 2015, 35, 225-285.	5.0	165
5	Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?. Current Medicinal Chemistry, 2014, 21, 553-574.	1.2	110
6	Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications. Medicinal Research Reviews, 2015, 35, 1220-1267.	5.0	93
7	NFAT as cancer target: Mission possible?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 297-311.	3.3	90
8	Natural Product Ginsenoside 25-OCH3-PPD Inhibits Breast Cancer Growth and Metastasis through Down-Regulating MDM2. PLoS ONE, 2012, 7, e41586.	1.1	73
9	The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models. Nature Communications, 2014, 5, 5086.	5.8	70
10	Oral nano-delivery of anticancer ginsenoside 25-OCH3-PPD, a natural inhibitor of the MDM2 oncogene: Nanoparticle preparation, characterization, <i>in vitro</i> and <i>in vivo</i> anti-prostate cancer activity, and mechanisms of action. Oncotarget, 2015, 6, 21379-21394.	0.8	57
11	Natural Product MDM2 Inhibitors: Anticancer Activity and Mechanisms of Action. Current Medicinal Chemistry, 2012, 19, 5705-5725.	1.2	56
12	RYBP expression is associated with better survival of patients with hepatocellular carcinoma (HCC) and responsiveness to chemotherapy of HCC cells <i>in vitro</i> and <i>in vivo</i> . Oncotarget, 2014, 5, 11604-11619.	0.8	46
13	Selective cytotoxicity, inhibition of cell cycle progression, and induction of apoptosis in human breast cancer cells by sesquiterpenoids from Inula lineariifolia Turcz European Journal of Medicinal Chemistry, 2013, 68, 473-481.	2.6	41
14	miRNAs in Cancer Prevention and Treatment and as Molecular Targets for Natural Product Anticancer Agents. Current Cancer Drug Targets, 2013, 13, 519-541.	0.8	33
15	In vitro metabolism of benzo[a]pyrene-7,8-dihydrodiol and dibenzo[def,p]chrysene-11,12 diol in rodent and human hepatic microsomes. Toxicology Letters, 2017, 269, 23-32.	0.4	17
16	Development and validation of a rapid HPLC method for quantitation of SPâ€141, a novel pyrido[b]indole anticancer agent, and an initial pharmacokinetic study in mice. Biomedical Chromatography, 2015, 29, 654-663.	0.8	12
17	Exposure to an Environmental Mixture of Polycyclic Aromatic Hydrocarbons Induces Hepatic Cytochrome P450 Enzymes in Mice. Chemical Research in Toxicology, 2021, 34, 2145-2156.	1.7	10
18	Advances in Translational Pharmacological Investigations in Identifying and Validating Molecular Targets of Natural Product Anticancer Agents. Current Cancer Drug Targets, 2013, 13, 596-609.	0.8	9

#	Article	IF	CITATIONS
19	A quantitative LC-MS/MS method for determination of SP-141, a novel pyrido[b]indole anticancer agent, and its application to a mouse PK study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 969, 235-240.	1.2	6
20	Pharmacokinetics and Pharmacodynamics in Breast Cancer Animal Models. Methods in Molecular Biology, 2016, 1406, 271-287.	0.4	3
21	Development and validation of an HPLC-MS/MS analytical method for quantitative analysis of TCBA-TPQ, a novel anticancer makaluvamine analog, and application in a pharmacokinetic study in rats. Chinese Journal of Natural Medicines, 2015, 13, 554-560.	0.7	2